Akif Turna1, Cem Horozoğlu2,3, Öncü Koç Erbaşoğlu3, Şeyda Ercan3, Özlem Küçükhüseyin3, Saime Turan3, Mehmet Tolgahan Hakan3,4, Hasan Volkan Kara1, Elvin Hekimoğlu5, Ümit Zeybek3, Ender Coşkunpınar6, Canan Cacına3, Arzu Ergen3, İlhan Yaylım3. 1. Department of Thoracic Surgery, Cerrahpaşa Medical Faculty, İstanbul University, İstanbul, Turkey. 2. Department of Medical Services and Techniques, Vocational School of Health Services, İstanbul Gelişim University, İstanbul, Turkey. 3. Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, Turkey. 4. Department of Biology, Hitit University, Art and Science Faculty Çorum, Turkey. 5. National Institutes of Health, Bethesda, USA. 6. Department of Internal Medicine, İstanbul University, İstanbul Faculty of Medicine İstanbul, Turkey.
Abstract
BACKGROUND: This study aims to investigate the possible relationships between epidermal growth factor receptor gene mutations, serum epidermal growth factor receptor levels, programmed death ligand gene expression levels and the risks and survivals of resectable nonsmall cell lung cancer patients. METHODS: Deoxyribonucleic acid isolation was performed from peripheral blood samples and tumor tissues. The mutation analysis was performed for epidermal growth factor receptor. Programmed death ligand 1 gene expression levels were examined pathologically and histopathologically following the tissue tracing of 36 non-small cell lung cancer patients (29 males, 7 females; mean age 60.1 years; range, 41 to 79 years) and analyzed using real-time polymerase chain reaction. Epidermal growth factor receptor serum levels were assessed in all patients. RESULTS: As a result of mutation analyses in 21 patients (28.5% of all adenocarcinoma patients), epidermal growth factor receptor mutation was determined in at least one exon in six patients. In epidermal growth factor receptor mutation detected patients, programmed death ligand 1 gene expression levels were associated with lymph node metastasis (p=0.036). However, epidermal growth factor receptor mutations were not statistically significantly associated according to histopathological examination (p>0.05). Of patients carrying exon 20 (c.2303G>T) mutations, 25% had tumors with perineural invasion. There was a statistically significant association between exon 20 insertions and c.2303G>T and lymphatic invasion (p=0.02), lymph node metastasis and exon 20 insertions (p=0.03). Patients with lower serum epidermal growth factor receptor levels (<400 pg/mL) had better survival time than those with higher serum epidermal growth factor receptor levels (p=0.04). CONCLUSION: Programmed death ligand 1 gene expression and epidermal growth factor receptor mutation might have a combined effect on non-small cell lung cancer. Programmed death ligand 1 gene expression in tumor pathology may also be a significant feature for tumor progression and tumorigenesis. Serum epidermal growth factor receptor levels seem to be associated with survival.
BACKGROUND: This study aims to investigate the possible relationships between epidermal growth factor receptor gene mutations, serum epidermal growth factor receptor levels, programmed death ligand gene expression levels and the risks and survivals of resectable nonsmall cell lung cancer patients. METHODS: Deoxyribonucleic acid isolation was performed from peripheral blood samples and tumor tissues. The mutation analysis was performed for epidermal growth factor receptor. Programmed death ligand 1 gene expression levels were examined pathologically and histopathologically following the tissue tracing of 36 non-small cell lung cancer patients (29 males, 7 females; mean age 60.1 years; range, 41 to 79 years) and analyzed using real-time polymerase chain reaction. Epidermal growth factor receptor serum levels were assessed in all patients. RESULTS: As a result of mutation analyses in 21 patients (28.5% of all adenocarcinoma patients), epidermal growth factor receptor mutation was determined in at least one exon in six patients. In epidermal growth factor receptor mutation detected patients, programmed death ligand 1 gene expression levels were associated with lymph node metastasis (p=0.036). However, epidermal growth factor receptor mutations were not statistically significantly associated according to histopathological examination (p>0.05). Of patients carrying exon 20 (c.2303G>T) mutations, 25% had tumors with perineural invasion. There was a statistically significant association between exon 20 insertions and c.2303G>T and lymphatic invasion (p=0.02), lymph node metastasis and exon 20 insertions (p=0.03). Patients with lower serum epidermal growth factor receptor levels (<400 pg/mL) had better survival time than those with higher serum epidermal growth factor receptor levels (p=0.04). CONCLUSION: Programmed death ligand 1 gene expression and epidermal growth factor receptor mutation might have a combined effect on non-small cell lung cancer. Programmed death ligand 1 gene expression in tumor pathology may also be a significant feature for tumor progression and tumorigenesis. Serum epidermal growth factor receptor levels seem to be associated with survival.
Authors: Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga Journal: Oncogene Date: 2003-05-08 Impact factor: 9.867
Authors: Manish R Patel; Blake A Jacobson; Yan Ji; Jeremy Drees; Shaogeng Tang; Kerry Xiong; Hengbing Wang; Jennifer E Prigge; Alexander S Dash; Andrea K Kratzke; Emily Mesev; Ryan Etchison; Mark J Federspiel; Stephen J Russell; Robert A Kratzke Journal: Oncotarget Date: 2015-10-20
Authors: Elena Yaiza Romero-Ventosa; Sonia Blanco-Prieto; Ana Lourdes González-Piñeiro; Francisco Javier Rodríguez-Berrocal; Guadalupe Piñeiro-Corrales; María Páez de la Cadena Journal: Springerplus Date: 2015-04-09
Authors: Hugo Arasanz; Maria Gato-Cañas; Miren Zuazo; Maria Ibañez-Vea; Karine Breckpot; Grazyna Kochan; David Escors Journal: Oncotarget Date: 2017-04-19